drugset / Trial / NCT00338780

Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

NCT00338780

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim is to investigate whether Lamivudine 100mg daily is effective in the long term treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia

Timeline

Start
2000-11
Primary completion
Completion
2005-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 100 mg